Q3 2026 Life Sciences Market Reports

"Overall vacancy declined 20 basis points (bps) year over year to 23.8%. Sublease vacancy fell 130 bps to 3.7%, reflecting reduced excess tenant space, while direct vacancy increased to 20.1%."

"Overall vacancy declined 240 basis points year over year to 36.9% from 39.3%, signaling a modest positive shift in the market and marking the second consecutive quarter of declining vacancy."

"Overall vacancy declined by 70 basis points year over year to 26.2% from 26.9% in Q3 2025, while available space decreased by 500,000 square feet to 1.1 million square feet."

"Overall vacancy decreased 50 basis points year over year to 22.8% from 23.3% in Q3 2025, while available space declined from 0.6 million square feet to 0.3 msf."

"Overall vacancy rose 80 basis points year over year to 24.8% but has remained relatively stable since jumping from 15.9% in Q2 2025 to 24.0% in Q3 2025."

"Overall vacancy increased 150 basis points year over year to 18.9%, driven by higher direct vacancy, while recent leasing and space withdrawals helped offset new availability."

"Overall vacancy declined by 10 basis points year over year while available space increased to 14.4 million square feet, up from 13.8 msf in Q3 2025."

"Overall vacancy increased 320 basis points year over year to 7.9%, up from 4.7% in Q3 2025. Despite the increase, Philadelphia continues to maintain one of the lowest vacancy rates among the nation’s leading life sciences markets."

"Overall vacancy declined 90 basis points year over year to 14.4%, supported by leasing activity and the withdrawal of several large blocks of available space. Direct vacancy fell to 11.9%, while sublease vacancy remained stable at 2.6%."

"Overall vacancy decreased 190 basis points year over year to 21.2%, while available space declined by 700,000 square feet (sf) to 2.5 million square feet."